AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20375185 — intervention group
Group type: EXPERIMENTAL
Intervention: UNIMMAP supplementation
Number of subjects: 1426
Study 20375185 — intervention group
Group type: COMPARATOR
Intervention: Growth-retarded infants
Number of subjects: 1426
Study 20375185 — intervention group
Group type: COMPARATOR
Intervention: Offspring of primiparae
Number of subjects: 1426
Study 18396293 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic strategies targeting endogenous cell sources
Number of subjects: 0
Study 18396293 — intervention group
Group type: EXPERIMENTAL
Intervention: Current therapeutic strategies in clinical trials
Number of subjects: 0
Study 16166413 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 0
Study 16166413 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 12472787 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression to microalbuminuria
Number of subjects: 5097
Study 12472787 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression from microalbuminuria to macroalbuminuria
Number of subjects: 5097
Study 12472787 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression from macroalbuminuria to elevated plasma creatinine or renal replacement therapy (RRT)
Number of subjects: 5097
Study 12472787 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual death rate for patients with elevated plasma creatinine or RRT
Number of subjects: 5097
Study 12472787 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk of cardiovascular death by nephropathy stage
Number of subjects: 5097
Study 12472787 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality risk comparison
Number of subjects: 5097
Study 10224345 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (2 g) given intravenously at the induction of anesthesia
Number of subjects: 1766
Study 10224345 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime (2 g) given intravenously at the induction of anesthesia
Number of subjects: 1766
Study 8903111 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein meal
Number of subjects: 0
Study 8903111 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat meal
Number of subjects: 0
Study 8903111 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate meal
Number of subjects: 0
Study 8903111 — intervention group
Group type: COMPARATOR
Intervention: Water ingestion (control)
Number of subjects: 0
Study 8903111 — intervention group
Group type: COMPARATOR
Intervention: Water loading (control)
Number of subjects: 0
Study 8903111 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat ingestion
Number of subjects: 0
Study 1828962 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron
Number of subjects: 32
Study 1828962 — intervention group
Group type: COMPARATOR
Intervention: Alizapride
Number of subjects: 32
Study 1828962 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron plus haloperidol
Number of subjects: 32
Study 6349538 — intervention group
Group type: EXPERIMENTAL
Intervention: Lentinan (LNT) administered intravenously at doses of 1 mg/person/day twice a week or 2 mg/person/day once a week in combination with mitomycin C + 5-FU (MF) or tegafur (FT)
Number of subjects: 0
Study 6349538 — intervention group
Group type: COMPARATOR
Intervention: Control therapy: MF or FT alone
Number of subjects: 0
Study 6349538 — intervention group
Group type: EXPERIMENTAL
Intervention: Lentinan (LNT) as supportive therapy for advanced or recurrent breast cancer
Number of subjects: 0
Study 31794512 — intervention group
Group type: EXPERIMENTAL
Intervention: St. John's wort (300 mg thrice daily)
Number of subjects: 16
Study 31794512 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 31376247 — intervention group
Group type: EXPERIMENTAL
Intervention: Formal statistical help acknowledged (Group I)
Number of subjects: 133
Study 31376247 — intervention group
Group type: COMPARATOR
Intervention: No formal statistical help acknowledged (Group II)
Number of subjects: 133
Study 28682677 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyhexanide/betaine gel
Number of subjects: 46
Study 28682677 — intervention group
Group type: COMPARATOR
Intervention: Silver sulfadiazine
Number of subjects: 46
Study 27483647 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectus Sheath Block (RSB)
Number of subjects: 34
Study 27483647 — intervention group
Group type: COMPARATOR
Intervention: Transversus Abdominis Plane Block (TAPB)
Number of subjects: 34
Study 27483647 — intervention group
Group type: EXPERIMENTAL
Intervention: Both RSB and TAPB
Number of subjects: 34
Study 25079928 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous ranibizumab (0.5 mg monthly)
Number of subjects: 610
Study 25079928 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuous ranibizumab (0.5 mg as-needed)
Number of subjects: 610
Study 25079928 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous bevacizumab (1.25 mg monthly)
Number of subjects: 610
Study 25079928 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuous bevacizumab (1.25 mg as-needed)
Number of subjects: 610
Study 25079928 — intervention group
Group type: COMPARATOR
Intervention: Continuous bevacizumab vs Discontinuous bevacizumab
Number of subjects: 610
Study 25079928 — intervention group
Group type: COMPARATOR
Intervention: Continuous ranibizumab vs Continuous bevacizumab
Number of subjects: 610
Study 23099331 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13
Number of subjects: 0
Study 23099331 — intervention group
Group type: COMPARATOR
Intervention: PCV7
Number of subjects: 0
Study 19531929 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous ART (viral suppression group; VS)
Number of subjects: 214
Study 19531929 — intervention group
Group type: COMPARATOR
Intervention: Intermittent ART (drug conservation group; DC)
Number of subjects: 214
Study 19531929 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous ART (VS)
Number of subjects: 214
Study 19531929 — intervention group
Group type: COMPARATOR
Intervention: Intermittent ART (DC)
Number of subjects: 214
Study 17288657 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye gaze angle of 7 degrees
Number of subjects: 53
Study 17288657 — intervention group
Group type: COMPARATOR
Intervention: Eye gaze angle of 15 degrees
Number of subjects: 53
Study 17288657 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived importance of eye contact difference
Number of subjects: 53
Study 15465622 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocytic dysfunction in early stage AD and DS
Number of subjects: 0
Study 15465622 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-immunofluorescence using Abeta antibodies
Number of subjects: 0
Study 15465622 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 0
Study 15465622 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-amyloid deposition in neuropathologically confirmed AD
Number of subjects: 0
Study 11204435 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoprotegerin (OPG) 3.0 mg/kg
Number of subjects: 0
Study 11204435 — intervention group
Group type: COMPARATOR
Intervention: Osteoprotegerin (OPG)
Number of subjects: 0
Study 9435420 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-like growth factor-I (IGF-I) at 5 micrograms/kg/h in a continuous s.c. infusion
Number of subjects: 8
Study 9435420 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) at 0.03 IU/kg/daily s.c. injection
Number of subjects: 8
Study 9435420 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline values)
Number of subjects: 8
Study 7905730 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human interferon gamma (0.1 mg subcutaneously for 10 days)
Number of subjects: 98
Study 7905730 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 7905730 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human interferon gamma
Number of subjects: 98
Study 2660252 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabumetone
Number of subjects: 0
Study 2660252 — intervention group
Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 0
Study 31676145 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥60 mL/kg/24 h
Number of subjects: 320
Study 31676145 — intervention group
Group type: COMPARATOR
Intervention: <60 mL/kg/24 h
Number of subjects: 320
Study 31641014 — intervention group
Group type: EXPERIMENTAL
Intervention: Timed 25‐Foot Walk (T25FW)
Number of subjects: 12776
Study 31641014 — intervention group
Group type: EXPERIMENTAL
Intervention: 9‐Hole Peg Test (9HPT)
Number of subjects: 12776
Study 31641014 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Contrast Letter Acuity (LCLA)
Number of subjects: 12776
Study 31641014 — intervention group
Group type: EXPERIMENTAL
Intervention: Symbol Digit Modalities Test (SDMT)
Number of subjects: 12776
Study 31641014 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional test battery (including T25FW, 9HPT, LCLA, SDMT)
Number of subjects: 12776
Study 31641014 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance measures (individual or multidimensional)
Number of subjects: 12776
Study 29167536 — intervention group
Group type: EXPERIMENTAL
Intervention: Model 1 (based on respiratory volume, respiratory rate, and age)
Number of subjects: 99
Study 29167536 — intervention group
Group type: EXPERIMENTAL
Intervention: Model 2 (incorporating activity categories, heart rate, sex, and BMI)
Number of subjects: 99
Study 25747391 — intervention group
Group type: EXPERIMENTAL
Intervention: APRN telehealth care coordination intervention
Number of subjects: 148
Study 25747391 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 148
Study 23458785 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoprene splint
Number of subjects: 119
Study 23458785 — intervention group
Group type: COMPARATOR
Intervention: Thermoplast splint
Number of subjects: 119
Study 22286628 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent sequential compression (ISC) of legs
Number of subjects: 100
Study 22286628 — intervention group
Group type: COMPARATOR
Intervention: Control group (without ISC)
Number of subjects: 100
Study 19224977 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich diet (58% carbohydrate, 27% fat, 15% protein)
Number of subjects: 164
Study 19224977 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsaturated-fat diet (48% carbohydrate, 37% fat, 15% protein)
Number of subjects: 164
Study 19224977 — intervention group
Group type: COMPARATOR
Intervention: Protein-rich diet (48% carbohydrate, 27% fat, 25% protein)
Number of subjects: 164
Study 17135809 — intervention group
Group type: EXPERIMENTAL
Intervention: ADL-PI self-rated version
Number of subjects: 644
Study 17135809 — intervention group
Group type: EXPERIMENTAL
Intervention: ADL-PI informant version
Number of subjects: 644
Study 17135809 — intervention group
Group type: EXPERIMENTAL
Intervention: MCI ADL questionnaire (informant version)
Number of subjects: 644
Study 12728216 — intervention group
Group type: COMPARATOR
Intervention: Plain yogurt
Number of subjects: 15
Study 12728216 — intervention group
Group type: COMPARATOR
Intervention: Plain kefir
Number of subjects: 15
Study 12728216 — intervention group
Group type: COMPARATOR
Intervention: Flavored yogurt
Number of subjects: 15
Study 12728216 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavored kefir
Number of subjects: 15
Study 10964334 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxil 35 mg/m2 every 3 weeks
Number of subjects: 45
Study 10964334 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxil 45 mg/m2 every 3 weeks
Number of subjects: 45
Study 10964334 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxil 50 mg/m2 every 4 weeks
Number of subjects: 45
Study 10964334 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxil 60 mg/m2 every 4 weeks
Number of subjects: 45
Study 10964334 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxil 65 mg/m2 every 5 weeks
Number of subjects: 45
Study 10964334 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxil 70 mg/m2 every 6 weeks
Number of subjects: 45
Study 10964334 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxil (various doses)
Number of subjects: 45
Study 8795600 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 40
Study 8795600 — intervention group
Group type: COMPARATOR
Intervention: Citalopram
Number of subjects: 40
Study 1463155 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone 1.25 mg/kg
Number of subjects: 7
Study 1463155 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 7
Study 3882290 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol treatment
Number of subjects: 0
Study 3882290 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29557401 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading (within 48 h)
Number of subjects: 54
Study 29557401 — intervention group
Group type: EXPERIMENTAL
Intervention: Early loading (at 6 weeks)
Number of subjects: 54
Study 29557401 — intervention group
Group type: COMPARATOR
Intervention: Conventional loading (at 3 months)
Number of subjects: 54
Study 26100763 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine closure technique with suture pulled in caudal direction (Group 1)
Number of subjects: 765
Study 26100763 — intervention group
Group type: COMPARATOR
Intervention: Uterine closure technique with suture pulled in cephalic direction (Group 2)
Number of subjects: 765
Study 26174905 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor screening for anti-A isoagglutinins
Number of subjects: 705
Study 23945905 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression (assessed using the 9-item Patient Health Questionnaire, scores ≥10)
Number of subjects: 2977
Study 21918214 — intervention group
Group type: EXPERIMENTAL
Intervention: Familiarity with snack foods
Number of subjects: 70
Study 21918214 — intervention group
Group type: EXPERIMENTAL
Intervention: Expected satiation
Number of subjects: 70
Study 19108662 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) at varying doses (placebo, 0.15 mg/kg t.i.d., 0.3 mg/kg t.i.d., and 0.6 mg/kg t.i.d.) combined with behavior modification therapy (BMOD) at three intensities (no, low, high) for 3 weeks each.
Number of subjects: 101
Study 19108662 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior modification therapy (BMOD) at three intensities (no, low, high) for 3 weeks each.
Number of subjects: 101
Study 19108662 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-SMD subjects).
Number of subjects: 101
Study 16298238 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain magnetic activity recorded during a memory task using magnetoencephalography.
Number of subjects: 15
Study 14622664 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine sulfate delivery system
Number of subjects: 149
Study 10831478 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine XR (75, 150, or 225 mg/day)
Number of subjects: 377
Study 10831478 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 377
Study 9335387 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mmol/L dialysate calcium
Number of subjects: 14
Study 9335387 — intervention group
Group type: COMPARATOR
Intervention: 1.25 mmol/L dialysate calcium
Number of subjects: 14
Study 8382725 — intervention group
Group type: EXPERIMENTAL
Intervention: RRVxDS-1 (serotype 2 vaccine)
Number of subjects: 25
Study 8382725 — intervention group
Group type: EXPERIMENTAL
Intervention: RRVxD (serotype 1 vaccine)
Number of subjects: 25
Study 2875673 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 different premedications
Number of subjects: 600
Study 2875673 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher anxiety levels in patients
Number of subjects: 600
Study 31556677 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (OT) 40 IU
Number of subjects: 60
Study 31556677 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 30646043 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning model predicting 30-day mortality from chemotherapy start
Number of subjects: 26946
Study 30646043 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning model predicting 30-day mortality among patients receiving palliative chemotherapy
Number of subjects: 26946
Study 30646043 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning model predicting 180-day mortality
Number of subjects: 26946
Study 26132048 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention offered once a day for 3 days
Number of subjects: 100
Study 26132048 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving routine care
Number of subjects: 100
Study 24754143 — intervention group
Group type: EXPERIMENTAL
Intervention: Locked plate fixation for 3-part fractures
Number of subjects: 64
Study 24754143 — intervention group
Group type: COMPARATOR
Intervention: Locked plate fixation for 4-part fractures
Number of subjects: 64
Study 23127308 — intervention group
Group type: EXPERIMENTAL
Intervention: Group physiotherapy intervention
Number of subjects: 111
Study 23127308 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 111
Study 21281126 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation
Number of subjects: 11
Study 21281126 — intervention group
Group type: EXPERIMENTAL
Intervention: iMINDr (custom monitoring software)
Number of subjects: 11
Study 17538544 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 000 IU vitamin A with BCG vaccination
Number of subjects: 2145
Study 17538544 — intervention group
Group type: COMPARATOR
Intervention: Placebo with BCG vaccination
Number of subjects: 2145
Study 16750701 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillator (ICD)
Number of subjects: 1095
Study 16750701 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical care
Number of subjects: 1095
Study 12691339 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight reduction programme (10% weight loss)
Number of subjects: 57
Study 10891823 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescents
Number of subjects: 127
Study 10891823 — intervention group
Group type: COMPARATOR
Intervention: Preadolescents
Number of subjects: 127
Study 8937963 — intervention group
Group type: EXPERIMENTAL
Intervention: Azole resistant strains of Candida
Number of subjects: 64
Study 8937963 — intervention group
Group type: COMPARATOR
Intervention: Azole susceptible strains of Candida
Number of subjects: 64
Study 8937963 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous use of azole therapy
Number of subjects: 64
Study 8937963 — intervention group
Group type: EXPERIMENTAL
Intervention: More than five episodes of oral candidosis in the last year
Number of subjects: 64
Study 8937963 — intervention group
Group type: EXPERIMENTAL
Intervention: C2-3 category of HIV infection
Number of subjects: 64
Study 8937963 — intervention group
Group type: EXPERIMENTAL
Intervention: Low number of circulating CD4+ T-cells
Number of subjects: 64
Study 1529684 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin 0.3 micrograms/kg BW
Number of subjects: 50
Study 1529684 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 2868748 — intervention group
Group type: COMPARATOR
Intervention: Fenoldopam 25, 50, or 100 mg (dose-ranging study)
Number of subjects: 13
Study 2868748 — intervention group
Group type: COMPARATOR
Intervention: Fenoldopam 100 mg (double-blind study)
Number of subjects: 13
Study 2868748 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam 100 mg (after 1 month of 4 times daily dosing)
Number of subjects: 13
Study 2868748 — intervention group
Group type: COMPARATOR
Intervention: Placebo (double-blind study)
Number of subjects: 13
Study 30388041 — intervention group
Group type: EXPERIMENTAL
Intervention: Stressful period (one week prior to an examination)
Number of subjects: 50
Study 30388041 — intervention group
Group type: COMPARATOR
Intervention: Nonstressful period (four weeks after an examination)
Number of subjects: 50
Study 27254809 — intervention group
Group type: EXPERIMENTAL
Intervention: CLEAR CARE
Number of subjects: 38
Study 27254809 — intervention group
Group type: EXPERIMENTAL
Intervention: OPTI‐FREE PureMoist
Number of subjects: 38
Study 27254809 — intervention group
Group type: COMPARATOR
Intervention: Biotrue
Number of subjects: 38
Study 27254809 — intervention group
Group type: COMPARATOR
Intervention: RevitaLens OcuTec
Number of subjects: 38
Study 24858821 — intervention group
Group type: EXPERIMENTAL
Intervention: Cloxacillin 4 g i.v. (intervention group)
Number of subjects: 8
Study 24858821 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (control group)
Number of subjects: 8
Study 21812009 — intervention group
Group type: EXPERIMENTAL
Intervention: Active exposure
Number of subjects: 20
Study 21812009 — intervention group
Group type: COMPARATOR
Intervention: Sham exposure
Number of subjects: 20
Study 20170904 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental Theory highlighting the possibility of self-improvement
Number of subjects: 25
Study 20170904 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 25
Study 18247077 — intervention group
Group type: EXPERIMENTAL
Intervention: ATS mechanical aortic valve
Number of subjects: 300
Study 18247077 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbomedics mechanical aortic valve
Number of subjects: 300
Study 18247077 — intervention group
Group type: EXPERIMENTAL
Intervention: St Jude Medical Hemodynamic Plus mechanical aortic valve
Number of subjects: 300
Study 18439587 — intervention group
Group type: EXPERIMENTAL
Intervention: Single medium
Number of subjects: 79
Study 18439587 — intervention group
Group type: COMPARATOR
Intervention: Sequential media system
Number of subjects: 79
Study 16355079 — intervention group
Group type: EXPERIMENTAL
Intervention: HRC PNF stretching
Number of subjects: 30
Study 16355079 — intervention group
Group type: EXPERIMENTAL
Intervention: CRC PNF stretching
Number of subjects: 30
Study 16355079 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 11258691 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF) DPI, 100 microg, twice daily
Number of subjects: 227
Study 11258691 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF) DPI, 200 microg, twice daily
Number of subjects: 227
Study 11258691 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) MDI, 168 microg, twice daily
Number of subjects: 227
Study 11258691 — intervention group
Group type: COMPARATOR
Intervention: Placebo DPI
Number of subjects: 227